Loading
Carboplatin / Cyclophosphamide / Breast Cancer · Phase 1 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 pilot trial registered to assess feasibility and toxicity of chemotherapy (paclitaxel, cyclophosphamide, carboplatin) in patients aged ≥70 years. No results have been posted in this registry record, and the study remains active but not recruiting. The work is intended to generate safety and tolerance data in an older population, a clinically important question, but cannot yet support any conclusion about efficacy, benefit, or comparative effectiveness.
Phase 1, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Breast Cancer; age from 70 Years. Intervention: Carboplatin + Paclitaxel; Cyclophosphamide + Paclitaxel. n = 41. 5 sites: United States.
This is a Phase 1 pilot trial registered to assess feasibility and toxicity of chemotherapy (paclitaxel, cyclophosphamide, carboplatin) in patients aged ≥70 years. No results have been posted in this registry record, and the study remains active but not recruiting. The work is intended to generate safety and tolerance data in an older population, a clinically important question, but cannot yet support any conclusion about efficacy, benefit, or comparative effectiveness.
Primary outcomes are feasibility and toxicity, not efficacy or survival.
Clinicians treating older breast cancer patients should note this trial is underway to generate safety data for standard chemotherapy regimens in this population, but results are not yet available in this registry record and should be awaited before drawing conclusions.
This is a Phase 1 pilot feasibility trial with no results posted; it measures toxicity and treatment completion in older patients but carries no outcome data to assess efficacy or comparative benefit.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians treating older breast cancer patients should note this trial is underway to generate safety data for standard chemotherapy regimens in this population, but results are not yet available in this registry record and should be awaited before drawing conclusions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT03858322). This is a study registration, not published results. Lead sponsor: Dana-Farber Cancer Institute. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 41 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DRUG: Paclitaxel; DRUG: Cyclophosphamide; DRUG: Carboplatin. Primary outcome measures: Toxicity and receipt of planned therapy (feasibility) , 3 months. Brief summary: This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.